Non-Valvular Atrial Fibrillation (NVAF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Valvular atrial fibrillation (AF) is a condition where AF occurs in the presence of mitral stenosis or mechanical valve prosthesis. On the other hand, non-valvular atrial fibrillation (NVAF) refers to an irregular and often rapid heartbeat in the heart’s atria. However, unlike valvular AF, it is not associated with significant heart valve issues. NVAF is the most prevalent form of atrial fibrillation. NVAF can have various nonvalvular causes, such as exposure to heart stimulants like alcohol, caffeine, or tobacco, sleep apnea, high blood pressure, lung problems, hyperthyroidism, or severe illness-related stress such as pneumonia. NVAF symptoms include discomfort in the chest, a fluttering feeling in the chest, palpitations, dizziness or near-fainting sensations, labored breathing, and fatigue. Atrial fibrillation is a common heart rhythm disorder that primarily affects the atria and significantly raises the risk of thromboembolic events, particularly ischemic stroke and systemic embolization. NVAF is a substantial risk factor for severe and potentially fatal ischemic strokes, contributing to approximately 15% of all ischemic strokes and up to 30% of strokes in individuals in their 80s. In the European Union, Dabigatran etexilate (Pradaxa) has received approval to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) who have one or more risk factors.

Thelansis’s “Non-Valvular Atrial Fibrillation (NVAF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Valvular Atrial Fibrillation (NVAF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Non-Valvular Atrial Fibrillation (NVAF) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Non-Valvular Atrial Fibrillation (NVAF) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Non-Valvular Atrial Fibrillation (NVAF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033